The liver performs several critical functions including filtering blood, detoxifying chemicals and metabolizing drugs. When the liver is damaged by hepatitis, alcohol, or primary liver disease, fibrosis ensues. Long-term ...
Nov 19, 2019
0
1
(HealthDay)—For patients with cirrhosis, predictors of death include age, body surface area (BSA), and Model for End-Stage Liver Disease (MELD), according to a study published online Sept. 13 in Hepatology.
Sep 26, 2017
0
0
Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related ...
Apr 24, 2017
0
0
Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. A new analysis indicates that following screening guidelines for HCC in cirrhotic patients is lifesaving and cost-effective compared ...
Feb 8, 2017
0
0
(HealthDay)—For patients with cirrhosis with previous spontaneous bacterial peritonitis (SBP), proton pump inhibitor (PPI) use is not associated with SBP recurrence, according to a study published online Nov. 7 in the Journal ...
Nov 10, 2016
0
0
Jasmohan Bajaj, M.D., associate professor at Virginia Commonwealth University, had findings from his research on gut bacteria in cirrhosis published recently in the journals Hepatology and Scientific Reports.
Jul 7, 2016
0
46
A Hepatitis C (HCV) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment, helped HCV genotype 3 patients with heavily scarred livers and no previous treatment history ...
Apr 16, 2016
0
4
(HealthDay)—For cirrhotic patients with acute variceal bleeding (AVB), being on non-selective beta-blockers (NSBB) is not a negative prognostic factor for short-term survival, according to a study published online Sept. ...
Sep 16, 2015
0
4
Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These ...
Apr 25, 2015
0
6
Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks ...
Apr 23, 2015
0
11
